Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2442469 | 0.90 | AAK1 (0.34) | CTSLCACNA1B | |
| SCHEMBL2441782 | 0.88 | CTSL (0.36) | CTSLTGM2KLK7P2RX7TACR1 | |
| SCHEMBL2446120 | 0.85 | CTSL (0.44) | CTSLPDE4BTGM2ITGB3ITGA2B | |
| SCHEMBL12299586 | 0.85 | CTSL (0.44) | CTSLPDE4BTGM2ITGB3ITGA2B | |
| SCHEMBL12299680 | 0.85 | CTSL (0.43) | CTSLPDE4BTGM2CACNA1BITGB3 | |
| SCHEMBL2442069 | 0.84 | SCN9A (0.33) | CTSLCACNA1B | |
| SCHEMBL13448807 | 0.83 | CTSL (0.40) | CTSLPDE4BTGM2CACNA1BITGB3 | |
| SCHEMBL12299720 | 0.83 | CTSL (0.40) | CTSLPDE4BTGM2CACNA1BITGB3 | |
| SCHEMBL2440601 | 0.82 | TGM2 (0.33) | TGM2 | |
| SCHEMBL13448815 | 0.81 | HTR2A (0.35) | CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | CTSL 134/4885PDE4B 1668/4885TGM2 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.